Interacting Drugs |
Doxepin (systemic) vs QTc-Prolonging Agents |
Security Level |
|
Mechanism |
QTc-Prolonging Agents: May enhance the adverse/toxic effect of other QTc-Prolonging Agents. Their effects can be additive, causing life-threatening ventricular arrhythmias. |
Management |
Consider therapy modification |
Doxepin (systemic) vs QTc-Prolonging Agents
Post Review about Doxepin (systemic) vs QTc-Prolonging Agents Click here to cancel reply.
Other Interactions of Doxepin (systemic)
Other Interactions of QTc-Prolonging Agents
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.